新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 胰腺癌生物标记物将有助于特效疗法的开发

胰腺癌生物标记物将有助于特效疗法的开发

来源:生物谷 2013-10-22 20:46

2013年10月22日讯 /生物谷BIOON/ --胰腺癌一直被认为是最难以治愈的癌症之一,现在研究人员发现使用一种名为phosphatidylserine的生物标记物将可能大大提高开发胰腺癌药物的成功率。phosphatidylserine是一种脂类生物标记物,能够定位在胰腺癌癌细胞细胞膜上。当phosphatidylserine和一种名为SapC-DOPS的细胞成分相连时就能有效杀灭胰腺癌癌细胞。目前该技术已经申请专利。(生物谷Bioon.com)详细英文报道:

Pancreatic cancer has long remained one of the toughest targets in the oncology drug field. But an investigator at the University of Cincinnati says targeting a biomarker known as phosphatidylserine (PS) could greatly improve the odds of coming up with an effective therapy.

Building on work that showed a combination of cellular components called SapC-DOPS can effectively kill a variety of cancer cells, the team, led by oncology investigator Xiaoyang Qi, notes that SapC-DOPS binds to phosphatidylserine, a lipid found on the membrane surfaces of pancreatic tumor cells. The work was published Oct. 4 in PLoS ONE.

"We observed that the nanovesicles selectively killed human pancreatic cancer cells, and the noncancerous, or untransformed, cells remained unaffected," Qi says. "This toxic effect correlated to the surface exposure level of PS on the tumor cells."

Qi added that the technology is now being licensed--the release didn't mention any company by name--and that clinical trials would begin soon.

"Dr. Qi's discovery has great potential to be developed into diagnostics and therapies for pancreatic cancer," says Shuk-mei Ho, director of the Cincinnati Cancer Center and Jacob G. Schmidlapp Professor and Chair of Environmental Health. "This type of research helps fulfill the mission of the National Cancer Institute to promote translation of research from the bench to the bedside."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库